CHDR1839: Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Diagnosis ALS
Study phase Recruiting
Participating centres UMC Utrecht

A Phase 1b randomized, placebo-controlled, double-blind, crossover study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL747 in subjects with Amyotrophic Lateral Sclerosis (ALS).

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis when administered for 29 days in a cross-over design.

Overall enrolment: 16 patients in Leiden, the Netherlands.

Read more on clinicaltrials.gov